Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Nanalysis Scientific misses Q2 estimates – stock falls double digits

Nanalysis Scientific reported Q2 revenue of 9.72 million CAD and EPS of $0.00, missing consensus estimates (expectation: 12.55 million CAD revenue, EPS $0.01). The stock plunged about 10% to $0.13 after the release. Operationally, adjusted EBITDA, gross margins and the net loss improved, while the company cut costs and realigned its business model more toward organic growth. Management expects a stronger second half, citing better sales activity and strategic measures (revamping the dealer network, direct sales, new products). » Altro su de.investing.com
Nanalysis Scientific misses Q4 2025 revenue forecast — shares plunge

Nanalysis Scientific reported revenue of CAD 10.68 million for Q4 2025, missing the CAD 12.1 million forecast by 11.74%, after which the shares fell 10.34% to CAD 0.13. Revenue declined 13% year on year, gross margins in product sales and security services decreased, adjusted EBITDA fell 33% and the normalized net loss amounted to CAD 729,000. Management cites problems in the scientific equipment segment, macroeconomic headwinds and supply‑chain challenges, but emphasizes capital strengthening, government funding, strategic partnerships and measures to stabilize margins. » Altro su de.investing.com
Nanalysis Scientific reports 12% revenue decline in Q3 2025 and launches realignment

Nanalysis Scientific posted a consolidated revenue decline of 12% to CAD 9.3 million in the third quarter of 2025 and a net loss of CAD 1.5 million, with gross margin on product sales falling from 52% to 44%. Adjusted EBITDA dropped to negative CAD 2,000 compared with a profit a year earlier. Management is driving a restructuring focused on proprietary technologies, expanding the services business and forging strategic partnerships to improve margins and long-term growth. In the near term, macroeconomic pressure, supply-chain problems and the discontinuation of resale activities are weighing on revenues. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, NANALYSIS SCIENTI ha registrato ricavi pari a 6,00M€ e un utile netto di −410,91k€

(EUR)	giu 2026	YoY
Ricavi	+6,00M	0,45%
Utile lordo	+1,05M	27,44%
Utile netto	−410,91k	68,95%
EBITDA	+368,95k	174,90%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+11,77M€
Numero di azioni	138,46M
Massimo/minimo a 52 settimane	+0,14€ - +0,0687€
Dividendi	No
Beta	-0,12
Rapporto P/E	−4,17
Rapporto PEG	−0,04
Rapporto P/B	+1,54
Rapporto P/S	+0,47

Profilo aziendale

Nanalysis Scientific Corp. entwickelt, produziert und vertreibt kompakte Kernspinresonanzspektrometer und Magnetresonanz-Bildgebungsgeräte für die Pharma-, Biotech-, Chemie-, Sicherheits-, Lebensmittel-, Material- und Bildungsindustrie. Das Unternehmen ist in drei Segmenten tätig: Nanalysis, RS2D, und Corporate. Das Unternehmen bietet auch Softwaremodulpakete an, produziert und vertreibt modernste Elektronikkomponenten für Präzisionsanalysegeräte und bietet Überwachungs- und Unterstützungsdienste für seine NMR-Technologien. Es vertreibt seine Produkte sowohl direkt als auch über ein weltweites Netz von Händlern. Der Hauptsitz des Unternehmens befindet sich in Calgary, Kanada.